Abstract
Introduction
Atrial fibrillation (AF) and heart failure (HF) are among the most common cardiovascular diseases being considered true epidemics.
AF is the most common heart rhythm disorder encountered in current global medical practice, and often the two pathologies coexist with similar risk factors.
When affecting in synchronicity, AF and HF have cumulative side effects, are associated with significantly increased morbidity and mortality, thus having a low prognosis. 1, 2 It is estimated that the prevalence of atrial fibrillation in developed countries is approximately 1.5-2% of the general population. Currently, the average age for 3 patients with this progressive disease is between 75 and 85 years; about one third of the paroxysmal AF episodes are completely asymptomatic, which means that the real numbers are much higher than estimated. 4 Heart failure is also a common disease in cardiovascular pathology, either in acute or chronic form, representing the final stage of progression of cardiovascular disease. It is a clinical syndrome characterized by the inability of the heart to provide a cardiac flow corresponding to the oxygen requirement at normal tissues level under normal venous pressure.
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H e a r t f a i l u r e h a s a p r e v a l e n c e o f approximately 2% in the general population, reaching a prevalence of more than 10% in patients over 65 years of age. More than 2% 6 o f a l l h o s p i t a l i z a t i o n s a r e d u e t o decompensated HF, and re-admittance 6 months after discharge can reach up to 50%.
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HF is the only growing disease in developed countries due to aging population and prolonging the life of cardiac patients. 
R h y t h m c o n t r o l s t r a t e g i e s i n v o l v e antiarrhythmic drugs or invasive procedures (catheter ablation or surgical intervention)
that present a significant risk, but that can assure the maintenance of sinus rhythm. 
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Recent advances in catheter ablation therapies for AF have been shown to be effective in well-selected patients with HF, resulting in significant improvement of cardiac function, symptoms and quality of life. 15 The prognostic significance of AF in HF patients remains controversial because there is no consensus demonstrating that AF is an independent risk factor for adverse outcomes.
Although HF patient rehospitalisation is a marker of severity and prognosis, it cannot be used as a surrogate for mortality, especially since in the first few weeks after discharge, mortality and re-admittances do not have the same trend. 
